July 27, 2026

Mesh Hysteropexy May Improve Long-Term Prolapse Outcomes

Both hysteropexy and hysterectomy produced durable symptom improvement, although the uterine-preserving repair was associated with fewer composite treatment failures over a decade of follow-up.

Conexiant

July 17, 2026

Can Sugammadex Lower Postsurgical Pulmonary Complications?

A large international randomized trial found fewer postoperative pulmonary complications with sugammadex vs. neostigmine following major abdominal or thoracic surgery, although the difference was driven primarily by reduced atelectasis.

Conexiant

June 18, 2026

Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.

Conexiant

June 16, 2026

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.

Conexiant

June 09, 2026

Tibial Implant Linked to UUI Improvement

In the single-arm TITAN 2 study, 61% of patients were responders at 12 months, but the trial lacked a sham control.

Conexiant

June 09, 2026

Tranexamic Acid Reduces Previa Bleeding

The composite endpoint reached statistical significance, but transfusion alone did not, and the single-country design may limit applicability across populations.

Conexiant

June 05, 2026

Certain Surgical Specialties See Greater Attrition

“Nearly one in every 10 surgeons left active clinical practice.”

Conexiant

May 27, 2026

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.

Conexiant

May 22, 2026

Gender Bias Found in Regional Surgery Survey

Women surgeons were more often perceived as targets of workplace discrimination despite similar perceived clinical judgment and surgical skill.

Conexiant

May 21, 2026

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Conexiant